DOI 10.5414/CPP48184

Int. Journal of Clinical Pharmacology and Therapeutics, Volume 48 - March (184 - 191)

Efficacy and tolerability of EPs 7630 in children and adolescents with acute bronchitis – A randomized, double-blind, placebo-controlled multicenter trial with a herbal drug preparation from Pelargonium sidoides roots

W. Kamin1, V. Maydannik2, F.A. Malek3, M. Kieser4
1 University Hospital Pediatrics, Mainz, Germany, 2 Pediatrics Faculty, National Medical University of Ukraine, Kiev, Ukraine, 3 Dr. Willmar Schwabe GmbH & Co. KG Pharmaceuticals, Clinical Research Department, Karlsruhe, 4 Institute of Medical Biometry, Informatics, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany

Abstract

Objective: The study aim was to demonstrate the efficacy and to investigate the tolerability of EPs 7630, a herbal drug preparation from Pelargonium sidoides roots, in the treatment of patients (1 – 18 years) with acute bronchitis outside the strict indication for antibiotics. Materials and methods: A total of 200 patients were randomized to receive either active drug containing EPs 7630 (1 – 6 years: 3 × 10 drops/d; > 6 – 12 years: 3 × 20 drops/d; > 12 – 18 years: 3 × 30 drops/d) or placebo for 7 consecutive days. Primary outcome measure: change in the total score of bronchitis-specific symptoms (BSS) from Day 0 to Day 7. Main secondary outcome measures: treatment outcome, patients’ satisfaction with treatment, onset of effect, bed rest. Results: From baseline to Day 7, the mean BSS score improved significantly more for EPs 7630 compared with placebo (3.4 ± 1.8 vs. 1.2 ± 1.8 points, p < 0.0001). On Day 7, treatment outcome was significantly better (p < 0.0001), satisfaction with treatment more pronounced (77.6% vs. 25.8%, p < 0.0001), onset of effect faster, and time of bed rest shorter as compared with placebo. Tolerability was similarly good in both groups. All adverse events were assessed as non-serious. Conclusion: EPs 7630 was shown to be efficacious and safe in the treatment of acute bronchitis in children and adolescents outside the strict indication for antibiotics with patients treated with EPs 7630 perceiving a more favorable course of the disease and a good tolerability as compared with placebo.

Author Details

Authors

  • W. Kamin1
  • V. Maydannik2
  • F.A. Malek3
  • M. Kieser4

Departments

  • 1 University Hospital Pediatrics, Mainz, Germany,
  • 2 Pediatrics Faculty, National Medical University of Ukraine, Kiev, Ukraine,
  • 3 Dr. Willmar Schwabe GmbH & Co. KG Pharmaceuticals, Clinical Research Department, Karlsruhe,
  • 4 Institute of Medical Biometry, Informatics, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany

Full Text

Add to Cart

Rights / Permissions

This section will be available soon


Shopping Overview
Type Qtty Price
Your basket is empty
View Cart